

Single-dose epidural bupivacaine vs placebo after lumbar decompression surgery: A Randomized controlled trial

Sem M. M. Hermans, MD¹, Aniek A. G. Lantinga-Zee, MD¹, Ruud Droeghaag, MD¹, Henk van Santbrink, MD, PhD^{2,3,4}, Wouter L. W. van Hemert, MD, PhD¹, Mattheus K. Reinders, PharmD, PhD⁵, Daisy M. N. Hoofwijk, MD, PhD⁶, Sander M. J. van Kuijk, PhD⁷, Kim Rijkers, MD, PhD^{2,3,8}, Inez Curfs, MD, PhD¹

The authors declare no competing interests.

The author(s) received no specific funding for this work.

¹ Department of Orthopaedic Surgery, Zuyderland Medical Center, Heerlen, the Netherlands

² Department of Neurosurgery, Maastricht University Medical Center, Maastricht, the Netherlands

³ Department of Neurosurgery, Zuyderland Medical Center, Heerlen, the Netherlands

⁴ Care and Public Health Research Institute (CAPHRI) Maastricht University, Maastricht, the Netherlands

⁵ Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Center, Heerlen, the Netherlands

⁶ Department of Anaesthesiology, Zuyderland Medical Center, Heerlen, the Netherlands

⁷ Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, the Netherlands

⁸ School for Mental Health & Neuroscience, Maastricht University, Maastricht, The Netherlands

Correspondence to: Sem M. M. Hermans, MD

Department of Orthopaedic Surgery, Zuyderland Medical Center, Heerlen, the Netherlands
6130 MB SITTARD-GELEEN

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Phone: +31 627453199

Email: semhermans@hotmail.com

Fax: +31 88 4596742

1 **KEY WORDS**

2 Decompressive lumbar surgery, laminectomy, interlaminar decompression, intraoperative
3 epidural analgesia, nonsteroidal analgesia, pain control, additional analgesics, hospital stay

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26 **ABSTRACT**

27 ***Introduction***

28 Adequate postoperative pain management following lumbar spinal decompression surgery is
29 important as it will lead to early mobilization, less complications and shorter hospital stay.

30 Opioid consumption should be limited due to their frequently accompanied side effects and
31 their addictive nature. During the final phase of lumbar decompression surgery, the epidural
32 space becomes easily accessible. This might be an ideal moment for surgeons to administer
33 an epidural bolus of analgesia, as a safe and effective method for post-operative pain relief.

34

35 ***Methods***

36 This is a double blind randomized controlled trial comparing a single intraoperative bolus of
37 epidural analgesia using bupivacaine 0.25% to placebo (NaCl 0,9%) and its effect on
38 postoperative pain following lumbar spinal decompression surgery. The primary outcome
39 was the difference in NRS pain between the intervention and placebo groups during the first
40 48h after surgery. It was hypothesized that the intervention group will have lower
41 postoperative NRS pain scores.

42

43 ***Results***

44 Both the intervention group and the placebo group consisted of 20 randomized patients
45 (N=40). We observed statistically significant lower NRS pain scores in the intervention group
46 in comparison with the control group, with a difference of -1.9 (± 1.1). The average pain score
47 was lower in the intervention group at all postoperative time-points. Opioid consumption,
48 quality of life and satisfaction were similar between study groups. No study related
49 complications occurred, and complications rate did not differ between study groups.

50

51 ***Conclusion***

52 This randomized controlled trial shows that administrating a bolus of intraoperative epidural
53 bupivacaine is a safe and effective method in reducing early postoperative pain following
54 lumbar decompression surgery.

55

56 **INTRODUCTION**

57 Neurogenic claudication due to lumbar spinal stenosis is one of the most common
58 degenerative spinal disorders.¹ The stenosis is typically a result of spondylosis of the lumbar
59 spine which narrows the spinal canal. Lumbar spinal stenosis mostly affects individuals over
60 the age of 60 years.² The incidence of degenerative spinal disorders is rising along with the
61 ageing of the population, leading to an increase in the number of lumbar decompression
62 surgeries.³ Neurogenic claudication due to lumbar spinal canal stenosis is usually surgically
63 treated. The most common procedures are laminectomy and interlaminar decompression.
64 The goal of these procedures is symptom relief, alleviating complaints of pain, numbness
65 and weakness of legs and buttocks.⁴

66 Adequate postoperative pain management is important as it will lead to early
67 mobilization, less complications and shorter duration of hospital stay.⁵ Opioids are often used
68 to attain these goals. Opioid consumption is frequently accompanied by unwanted side
69 effects, such as respiratory depression, constipation, and nausea, which might influence
70 mobilization and length of hospital stay.⁶ Moreover, patients tend to continue the use of
71 prescribed postoperative analgesics, including opioids, after discharge because of their
72 addictive nature.^{7,8} This will worsen the current societal problems related to chronic opioid
73 use in Western countries.^{9,10}

74 During the final phase of lumbar decompression surgery, the epidural space is
75 exposed and easily accessible for administration of an epidural bolus of analgesia. This can
76 be a safe and effective method for immediate post-operative pain relief. Current literature on
77 epidural administration of intraoperative analgesics in lumbar decompression surgery is
78 heterogeneous. No consensus exists concerning the optimal technique for postoperative
79 pain reduction. Several administrative methods and agents can be considered, including

80 steroids.^{11–15} Although epidural administration of steroids has the potential to reduce
81 postoperative pain in patients undergoing lumbar decompression surgery, there are several
82 concerns regarding its use.^{13,14,16} The main concern is the increased risk of surgical site
83 infection and possibly epidural abscesses.^{17,18} According to some studies, non-steroidal
84 analgesics (i.e. amide, morphine) administered to the epidural space may similarly achieve
85 postoperative pain reduction, without the increased risk of infections.^{19–23}

86 Controversy remains regarding the effectiveness and safety of intraoperative epidural
87 application of analgesics. Therefore, an RCT comparing epidural analgesia using
88 bupivacaine 0.25% to placebo (NaCl 0,9%) was designed to investigate the added value of
89 an intraoperative epidural non-opioid analgesic. Results of this study will provide evidence-
90 based treatment recommendations.

91

92 **METHODS**

93 ***Study design***

94 This was a prospective, double blind, randomized controlled trial (RCT). Patients, clinicians,
95 researchers and the statistician were blinded. Only the pharmacy personnel were not.
96 Recruitment took place between 4 December 2020 and 16 January 2022. This study was
97 registered in the Dutch National TrialRegistry (registration number: NL8030; currently
98 transferred to the International Clinical Trial Registry Platform, ICTRP,
99 <https://trialssearch.who.int/Trial2.aspx?TrialID=NL8030>) and was written in accordance with
100 the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement.²⁴ Ethical
101 approval has been granted by the Medical Ethical Committee Zuyderland, Heerlen, the
102 Netherlands (registration number: Z20190138).

103

104 ***Study population***

105 Adult patients referred to the neurosurgical or orthopedic outpatient clinic who were
106 candidates for open lumbar spine decompression surgery (laminectomy and interlaminar
107 decompression) were eligible to participate in this RCT. Neurosurgeons and orthopedic

108 surgeons referred these eligible patients to the researchers (SH and AL). The researchers
109 informed the patients. Patients were included after informed consent in writing was obtained.

110 Patients with any of the following criteria were excluded from participation in this
111 study: preoperative opioid use, previous radiotherapy at the intended surgical level,
112 (progressive) motor failure and/or anal sphincter disorders which urges instant intervention,
113 active spinal inflammation/infection, immature bone (ongoing growth), pregnancy, contra-
114 indications for the use of bupivacaine or other amide-type local anesthetics, and/or
115 inadequate command of the Dutch language.

116

117 ***Interventions***

118 After receiving antibiotic prophylaxis, the patient was brought under general anesthesia. All
119 patients were intubated and then positioned in prone position. Short-acting opioids like
120 sufentanil or fentanyl were used during surgery. To prevent the influence of long-acting
121 opioids (e.g. morphine and piritramide) on the postoperative pain and therefore obscuring the
122 result of the epidural analgesia, no morphine was administered during or at the end of
123 surgery. A midline approach was performed, exposing the posterior lumbar elements
124 including the facet joints. The spinal canal was decompressed through a laminectomy or
125 interlaminar decompression. At the end of surgery, an epidural catheter was directly placed
126 under the most superiorly exposed lamina and placed at minimum 5 to maximum 10 cm
127 upward, depending on the level. The spreader was removed, and the wound was thoroughly
128 irrigated with saline and closed. After closure of the fascia, 5 cc of the study solution, which
129 was prepared and blinded by the pharmacy, was applied to the catheter. Either bupivacaine
130 0.25% (intervention) or NaCl 0.9% (placebo) was administrated. The catheter was removed
131 immediately after administration of the bolus. The wound was closed without suction
132 drainage. Patients who signed informed consent but were not eligible for randomization
133 (dural tear or inability to place catheter) received the standard of care. Postoperatively,
134 patients were transported to the recovery room, where they were monitored for a least one
135 hour.

136

137 **Outcomes**

138 The primary outcome was the average difference in NRS pain (0 - 10, 10 being 'worst pain
139 imaginable') between intervention and placebo during the first 48h after surgery. NRS pain
140 measurement was specific to the surgery site. With interval measurements at recovery entry,
141 recovery exit, 2, 4, 6, 24 and 48 hours postoperatively. Cumulative opioid use was also
142 monitored at recovery, 2, 4, 6, 24 and 48h postoperatively. Patients were able to receive
143 additional analgesia until $NRS \leq 3$. Health related quality of life and patient satisfaction were
144 measured using EuroQol-5D (EQ-5D) and General Surgery Recovery Index (GSRI) to
145 determine whether epidural analgesia leads to a better outcome than placebo. Patients filled
146 out the questionnaires 24 hours after surgery. Adverse events such as dural tear,
147 postoperative infection, deep venous thrombosis, hematoma, neurological deficits and other
148 medical complications such as pneumonia, urine retention or urinary tract infection were also
149 monitored up to 30 days following surgery. Length of hospital stay (days) was evaluated as
150 time between hospital admission and discharge.

151

152 **Randomization and blinding**

153 Allocation took place at the end of surgery after the epidural catheter was inserted. In case of
154 a dural tear or inability to place the epidural catheter, patients were referred to the cohort
155 group who received standard care. The pharmacy prepared blinded syringes with either
156 bupivacaine or NaCl. The pharmacy marked the syringes with a kit-number (1,2,3 etc).
157 These numbers corresponded with a computer-generated randomization list which was
158 stored by the pharmacy. Syringes were prepared once a week under aseptic conditions, and
159 stored at the pharmacy. They were collected at the end of the day, one day before a study
160 patient was operated on. Upon leaving the pharmacy, syringes were stored at the OR
161 complex at room temperature for maximally 24 hours. When a patient was eligible for
162 randomization (placement of catheter had been successful) the first successive syringe was
163 used. The surgeon noted the kit-number in the patient's electronic file. Once the study was

164 finished, the randomization list was unblinded by the pharmacy to clinicians, researchers,
165 statisticians and patients.

166

167 ***Statistical methods***

168 The primary endpoint is the difference in pain between the intervention group and the control
169 group. The sample size calculation was based on the difference between the intervention and
170 control group in NRS at recovery entry and exit following surgery. Own historical data showed
171 a standard deviation of 2 in NRS scores. A two-point reduction on the eleven-points (0 to 10)
172 NRS pain score was considered clinically relevant.^{25,26} In order to obtain a clinically meaningful
173 effect with 80% power, we needed 16 patients per group. When taking into account a 20% loss
174 to follow-up, 40 patients (20 patients per group) were enrolled in this study.

175 Frequency tables were provided for all categorical demographic information.
176 Continuous variables were presented as mean \pm standard deviation (SD) or median \pm
177 interquartile range (IQR) depending on the distribution of the data. Analysis was performed by
178 principal investigators using IBM SPSS statistical software package version 27 (SPSS Inc.,
179 Chicago, IL). Missing values were imputed using stochastic regression imputation using full
180 conditional specification. Data was tested for normal distribution. When data was normally
181 distributed the independent-samples t-test was used to determine statistical difference
182 between groups (e.g. NRS pain score, cumulative opioid use). In case of absence for normal
183 distribution, Wilcoxon's Signed-Rank test was used. In addition, the group differences over
184 time were determined (e.g., slopes of the relation between time and pain) using a linear mixed-
185 effects model with a random intercept on patient-ID and slope of time. The model included
186 group and time as fixed factors, and the interaction between group and time. Categorical data
187 was compared between groups using Pearson's Chi-Square test and Fisher's exact test. A p-
188 value ≤ 0.05 was considered statistically significant.

189

190 **RESULTS**

191 ***Study population and surgical characteristics***

192 Patients' characteristics are described in Table 1. A total of 44 patients were included in this
193 RCT. Four patients were not randomized due to a dural tear intraoperatively and thus
194 received standard care. Twenty patients were randomized to the intervention group
195 (bupivacaine), and 20 patients to the control group (placebo NaCl). All of these patients
196 received the allocated treatment as per protocol. Surgical characteristics are described in
197 Table 2. There was a significant difference in blood-loss between the intervention and control
198 group ($p=0.008$). Two complications occurred in the first 30 days following surgery. There
199 was no statistically significant difference in rate of complications between the study groups.

200

201 **Primary outcome**

202 Baseline NRS pain score did not statistically significantly differ between study groups ($p =$
203 0.115). Statistically significant lower mean NRS pain scores were observed in the
204 intervention group in comparison with the control group postoperatively ($-1.9 (\pm 1.1)$,
205 $p=0.013$). No statistically significant effect was observed for time ($p=0.119$) and group-
206 differences also did not significantly change over time (time*group-interaction, $p=0.113$). In
207 Figure 1 the pre- and postoperative NRS pain score is outlined for both study groups.

208

209 **Secondary outcome**

210 Perioperative opioid use was not statistically significantly different between intervention and
211 control group (Figure 2). Thirty-eight patients (95%) received sufentanil, one patient received
212 alfentanil (3%), one patient received remifentanil (3%), and six patients also received
213 piritramide (15%). Postoperatively, 28 patients received piritramide (70%), five patients
214 received oxycodone (13%), and two patients received morphine IV (5%).

215 EQ-5D and GSRI outcomes at 24 hours postoperatively did not reveal any differences
216 between study groups. EQ-5D score was 0.655 and 0.717 and GSRI was 70.18 and 63.50
217 for intervention group and placebo group, respectively.

218

219 **Standard care**

220 Four patients received standard care, as randomization for either the intervention or control
221 group did not take place due to a perioperative dural tear. In this group, two patients (50%)
222 were diabetic. None of these four patients had a history of spine surgery, and none smoked.
223 There were no relevant differences in baseline or surgical characteristics between the four
224 patients that received standard care and the other two groups. Besides the four dural tears,
225 no complications occurred in the standard care group.

226 Mean preoperative NRS was 0 (N=2). The mean NRS score at the time of entrance at
227 recovery was 2.5 (N=4), and 2.3 (N=4) upon departure from the recovery. At 2, 4, 6, and 24
228 hours postoperatively, the mean NRS scores were 2.0 (N=2), 1.5 (N=2), 0.3 (N=3), and 0.3
229 (N=3), respectively. NRS at 48 hours postoperatively was not available for any of these
230 patients.

231 Mean EQ-5D and GSRI 24 hours postoperatively was 0.834 (N=4) and 76.50 (N=4),
232 respectively. The peri-operative opioid use was the equivalent of 191mg (\pm 234mg) orally
233 administered morphine. Opioid use at recovery was 28mg (\pm 18), and the opioid use within
234 the first 48 hours postoperatively after discharge from recovery was 0mg.

235

236 **DISCUSSION**

237 This study gives new insight in the value of intraoperative epidural analgesia using
238 bupivacaine compared to placebo following lumbar decompression surgery. The most
239 important discovery is that immediate post-operative pain scores are reduced with
240 bupivacaine. The average pain score during all postoperative hours was low to moderate
241 (NRS < 3.5) in all study groups. Because of these low values, the difference in pain scores
242 between study groups appears minimal. However, at entry of the recovery and 2 hours
243 postoperatively NRS of the control group is twice as high as the intervention group.
244 In the intervention group, a reduction of >2 NRS points is observed at the first three
245 postoperative timepoints, which is not the case in the control group. The difference in pain
246 scores between intervention and control group decreases at later postoperative hours. This

247 may be explained by the fact that the effect of the bupivacaine bolus is worn off, as the
248 elimination half-life is approximately three hours.²⁷

249 No differences are observed in total opioid consumption between study groups in the
250 postoperative period. Although we expected that total opioid consumption would be lower in
251 the intervention group compared to the placebo group, it should be noted that equal opioid
252 consumption across groups is established with lower reported pain in the intervention group.
253 This shows that better pain control is achieved in the intervention group while consuming the
254 same number of opioids. Additionally, the sample size of the current study is calculated
255 based on difference in pain scores between intervention group and control group. Possibly, a
256 different sample size is required to investigate the difference in postoperative opioid
257 consumption after epidural bupivacaine administration. This might explain the discrepancy
258 between our current findings and the systematic review and meta-analysis we previously
259 performed regarding intraoperative epidural analgesia for pain relief after lumbar
260 decompressive spine surgery.²⁸ It is noteworthy that most studies investigating postoperative
261 analgesia consumption describe a significant decrease in pain in the treatment group.
262 However, only one study investigated postoperative opioid consumption, which dated from
263 1992.²⁹ Other studies investigated tramadol or diclofenac consumption following surgery.
264 Most of the included studies in our review implemented morphine as their analgesic agent. It
265 is recognized that epidural administration of morphine increases the risk for urinary
266 retention.³⁰ Non-opioid analgesics, such as bupivacaine, might be the key to bypass
267 complications linked to epidural analgesics administration. In the current study, not a single
268 patient displayed symptoms of urinary retention. The complications observed in this study
269 are related to wound healing, for which one patient received additional surgical intervention
270 and antibiotic treatment. Wound healing related complications are inherent to surgical
271 procedures and the numbers we report are in line with current literature.³¹ Several methods
272 of delivering local or regional analgesia during spine surgery are described in current
273 literature.²⁸ In this study we choose to use a catheter to deliver the bolus as it has the
274 possibility to be delivered more rostrally, resulting in a potential more immediate effect

275 compared to sponges or direct application. Furthermore, a bolus rather than a continuous
276 infusion was used as patients were encouraged to mobilize as soon as possible following
277 surgery. Also, maintaining catheters in situ postoperatively increases the risk for infection.³²

278 In the 24 hours following surgery, both EQ-5D and GSRI scores are high in all
279 patients. These scores indicate that the majority of patients recovers well one day
280 postoperatively and may also indicate that the difference in pain score across groups does
281 not influence the perceived health-related quality of life and patient satisfaction. One can
282 therefore wonder to what extent the different pain scores are clinically relevant. Nonetheless,
283 this study was not powered on EQ-5D or GSRI, thus making assumptions based on these
284 outcome data must be done with caution. The overall length of hospital stay was low, with a
285 mean of 1.7 days across all study groups. This indicates that most patients left the hospital
286 the second postoperative day. Current literature describes a mean length of stay of 2.1 days
287 for patients following elective laminectomy.³³ This small difference might be explained by
288 intercontinental differences in studies.

289 Finally, in a small group of patients (N=4) a perioperative dural tear occurred. These
290 patients received standard care, as administering an epidural bolus is deemed unsafe. In
291 this group, the perioperative opioid use is higher compared to intervention and control
292 groups. This is expected as exclusion from receiving a bolus of placebo or bupivacaine
293 meant the patient was able to receive long-acting opioids during surgery. Since the standard
294 care group consisted of four patients, statistical tests to compare this group with the other
295 two groups is not deemed meaningful.

296

297 **Limitations**

298 This study is bound by some important limitations. First, there is some missing outcome data.
299 This is mainly the result of delayed or missed measurement moments. At the 48-hour
300 measurement interval, the missing data is for the most part caused by the discharge of
301 patients before measurement. One can suppose that NRS pain score was low, considering a
302 patient is able to be discharged from the hospital. Percentage completed interval

303 measurements were; recovery entry (100%), recovery exit (100%), two hours (84%), four
304 hours (84%), six hour (91%), 24 hours (86%), and 48 hours postoperatively (27%). There
305 were no statistically significant differences in rates of missing data between intervention and
306 control group.

307 Second, a possible bias might have been introduced as some recovery nurses
308 consistently administer opioids when patients return from OR, as they expect the patient to
309 have pain. Our protocol describes that patients should only receive additional analgesia
310 when NRS > 3. Not all personnel followed these guidelines at the start of the study.

311 Third, the primary outcome of this study is the NRS pain score, which is at risk for
312 some sort of subjective discrepancies between patients. As is the case for all patient related
313 outcome measurements used in this study, being the EQ-5D and GSRI. Postoperative opioid
314 consumption is an objective outcome of this study, however no differences between study
315 groups were observed. Further research to reduce opioid consumption is relevant, as opioid
316 consumption should be limited after surgery, given its known side effects and growing
317 societal problems related to chronic opioid use, especially in surgical patients.^{9,10} In the US
318 the opioid epidemic was initially driven by increased consumption and availability of
319 pharmaceutical opioids. However, an increasing number of opioid overdoses are now related
320 to heroin and illicitly manufactured fentanyl and fentanyl analogs.³⁴ Addressing this epidemic
321 requires, among others, reducing opioid consumption in hospital setting. In some cases, it
322 might be possible to omit opioids completely during an admission for lumbar decompression
323 surgery. Ten patients (50%) in the treatment group and eight patients (40%) in the placebo
324 group did not receive any morphine during their postoperative period. Patients should only
325 receive opioids when pain is not adequately managed.

326

327 **CONCLUSION**

328 This randomized controlled trial indicates that administrating a bolus of intraoperative epidural
329 bupivacaine is a safe and effective method to reduce early postoperative pain following lumbar

330 decompression surgery. This method of analgesia may be a useful adjunct in patients
331 undergoing decompressive lumbar spine surgery.

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358 **REFERENCES**

- 359 1. Genevay S, Atlas SJ. Lumbar spinal stenosis. *Best Pract Res Clin Rheumatol*.
360 2010;24(2):253-265. doi:10.1016/j.berh.2009.11.001
- 361 2. Försth P, Ólafsson G, Carlsson T, et al. A Randomized, Controlled Trial of Fusion
362 Surgery for Lumbar Spinal Stenosis. *N Engl J Med*. 2016;374(15):1413-1423.
363 doi:10.1056/NEJMoa1513721
- 364 3. O'Lynnngier TM, Zuckerman SL, Morone PJ, Dewan MC, Vasquez-Castellanos RA,
365 Cheng JS. Trends for Spine Surgery for the Elderly: Implications for Access to
366 Healthcare in North America. *Neurosurgery*. 2015;77 Suppl 4:S136-41.
367 doi:10.1227/NEU.0000000000000945
- 368 4. Overdevest GM, Jacobs W, Vleggeert-Lankamp C, Thomé C, Gunzburg R, Peul W.
369 Effectiveness of posterior decompression techniques compared with conventional
370 laminectomy for lumbar stenosis. *Cochrane Database Syst Rev*. Published online
371 2015. doi:10.1002/14651858.CD010036.pub2
- 372 5. Guilfoyle MR, Mannion RJ, Mitchell P, Thomson S. Epidural fentanyl for postoperative
373 analgesia after lumbar canal decompression: a randomized controlled trial. *Spine J*.
374 2012;12(8):646-651. doi:10.1016/j.spinee.2012.07.007
- 375 6. Kurteva S, Abrahamowicz M, Gomes T, Tamblyn R. Association of Opioid
376 Consumption Profiles After Hospitalization With Risk of Adverse Health Care Events.
377 *JAMA Netw open*. 2021;4(5):e218782. doi:10.1001/jamanetworkopen.2021.8782
- 378 7. Connolly 3rd J, Javed Z, Raji MA, Chan W, Kuo Y-F, Baillargeon J. Predictors of
379 Long-term Opioid Use Following Lumbar Fusion Surgery. *Spine (Phila Pa 1976)*.
380 2017;42(18):1405-1411. doi:10.1097/BRS.0000000000002133
- 381 8. Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. Chronic Opioid Use after Surgery:
382 Implications for Perioperative Management in the Face of the Opioid Epidemic. *Anesth*
383 *Analg*. Published online 2017. doi:10.1213/ANE.0000000000002458
- 384 9. Lipman A, Webster L. The Economic Impact of Opioid Use in the Management of
385 Chronic Nonmalignant Pain. *J Manag care Spec Pharm*. 2015;21(10):891-899.

- 386 doi:10.18553/jmcp.2015.21.10.891
- 387 10. Dasgupta N, Beletsky L, Ciccarone D. Opioid Crisis: No Easy Fix to Its Social and
388 Economic Determinants. *Am J Public Health*. Published online 2018.
389 doi:10.2105/AJPH.2017.304187
- 390 11. K.J. G, A.P. B, A. A, J.L. B, L.N. H, K.J. B. Lumbar discectomy: Use of an epidural
391 morphine sponge for postoperative pain control. *Neurosurgery*. 1995;36(6):1131-1136.
392 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed5&NEWS=N&A](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed5&NEWS=N&AN=25166484)
393 [N=25166484](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed5&NEWS=N&AN=25166484)
- 394 12. Jamjoom BA, Jamjoom AB. Efficacy of intraoperative epidural steroids in lumbar
395 discectomy: a systematic review. *BMC Musculoskelet Disord*. 2014;15(1):146.
396 doi:10.1186/1471-2474-15-146
- 397 13. Wilson-Smith A, Chang N, Lu VM, et al. Epidural Steroids at Closure After
398 Microdiscectomy/Laminectomy for Reduction of Postoperative Analgesia: Systematic
399 Review and Meta-Analysis. *World Neurosurg*. Published online 2018.
400 doi:10.1016/j.wneu.2017.10.133
- 401 14. Ranguis SC, Li D, Webster AC. Perioperative epidural steroids for lumbar spine
402 surgery in degenerative spinal disease: A review. *J Neurosurg Spine*. Published online
403 2010. doi:10.3171/2010.6.SPINE09796
- 404 15. Waqas M, Shallwani H, Shamim M, Ahmad K. Perioperative steroids for lumbar disc
405 surgery: A meta-analysis of randomized controlled trials. *Surg Neurol Int*. Published
406 online 2017. doi:10.4103/sni.sni_478_16
- 407 16. Akinduro OO, Miller BA, Haussen DC, Pradilla G, Ahmad FU. Complications of
408 intraoperative epidural steroid use in lumbar discectomy: a systematic review and
409 meta-analysis. *Neurosurg Focus*. 2015;39(4):E12. doi:10.3171/2015.7.FOCUS15269
- 410 17. Lowell TD, Errico TJ, Eskenazi MS. Use of epidural steroids after discectomy may
411 predispose to infection. *Spine (Phila Pa 1976)*. Published online 2000.
412 doi:10.1097/00007632-200002150-00020
- 413 18. Aljabi Y, El-Shawarby A, Cawley DT, Aherne T. Effect of epidural methylprednisolone

- 414 on post-operative pain and length of hospital stay in patients undergoing lumbar
415 microdiscectomy. *Surgeon*. Published online 2015. doi:10.1016/j.surge.2014.03.012
- 416 19. McNeill TW, Andersson GB, Schell B et al. Epidural administration of
417 methylprednisolone and morphine for pain after a spinal operation: A randomized
418 prospective, comparative study. *J Bone Joint Surg Am*. 1995;77(12):1814-1818.
419 doi:10.2106/00004623-199512000-00004
- 420 20. M.K. G, V. S, P. P, L.S. M. A prospective randomized comparative study of gelfoam
421 soaked nalbuphine vs. Ketamine placed in epidural space during lumber spine surgery
422 for postoperative analgesia. *Anaesthesia, Pain Intensive Care*. 2018;22(4):492-498.
423 <http://www.apicareonline.com/index.php/APIC/article/view/1035/1720>
- 424 21. Mishra LD, Nath SS, Gairola RL, Verma RK, Mohanty S. Buprenorphine-soaked
425 absorbable gelatin sponge: An alternative method for postlaminectomy pain relief. *J*
426 *Neurosurg Anesthesiol*. Published online 2004. doi:10.1097/00008506-200404000-
427 00002
- 428 22. Kumari K, Kamal M, Singariya G, Kishan R, Garg S, Thanvi S. Effect of epidural
429 levobupivacaine with or without dexamethasone soaked in gelfoam for postoperative
430 analgesia after lumbar laminectomy: A double blind, randomised, controlled trial.
431 *Indian J Anaesth*. Published online 2018. doi:10.4103/ija.IJA_128_18
- 432 23. M.R. G, R.J. M, P. M. Epidural fentanyl for postoperative analgesia after lumbar canal
433 decompression: a randomized controlled trial. *Spine J*.
434 doi:<http://dx.doi.org/10.1016/j.spinee.2012.07.007>
- 435 24. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations
436 for improving the quality of reports of parallel-group randomized trials. *JAMA*.
437 2001;285(15):1987-1991. doi:10.1001/jama.285.15.1987
- 438 25. Salaffi F, Stancati A, Silvestri C, Ciapetti A. Minimal clinically important changes in
439 chronic musculoskeletal pain intensity measured on a NRS. *Eur J Pain*. 2004;8:283-
440 291. doi:10.1016/j.ejpain.2003.09.004
- 441 26. Myles PS, Myles DB, Galagher W, et al. Measuring acute postoperative pain using the

- 442 visual analog scale: The minimal clinically important difference and patient acceptable
443 symptom state. *Br J Anaesth*. Published online 2017. doi:10.1093/bja/aew466
- 444 27. Morishima HO, Ishizaki A, Zhang Y, Whittington RA, Suckow RF, Cooper TB.
445 Disposition of Bupivacaine and Its Metabolites in the Maternal, Placental, and Fetal
446 Compartments in Rats. *Anesthesiology*. 2000;93(4):1069-1074.
447 doi:10.1097/00000542-200010000-00031
- 448 28. Hermans SMM, Lantinga-Zee AAG, Rijkers K, et al. Intraoperative epidural analgesia
449 for pain relief after lumbar decompressive spine surgery: A systematic review and
450 meta-analysis. *Brain and Spine*. 2021;1:100306.
451 doi:<https://doi.org/10.1016/j.bas.2021.100306>
- 452 29. Bourke DL, Spatz E, Motara R, Ordia JI, Reed J, Hlavacek JM. Epidural opioids during
453 laminectomy surgery for postoperative pain. *J Clin Anesth*. 1992;4(4):277-281.
454 doi:10.1016/0952-8180(92)90128-n
- 455 30. Baldini G, Bagry H, Aprikian A, Carli F. Postoperative urinary retention: anesthetic and
456 perioperative considerations. *Anesthesiology*. 2009;110(5):1139-1157.
457 doi:10.1097/ALN.0b013e31819f7aea
- 458 31. Chahoud J, Kanafani Z, Kanj SS. Surgical site infections following spine surgery:
459 eliminating the controversies in the diagnosis. *Front Med*. 2014;1:7.
460 doi:10.3389/fmed.2014.00007
- 461 32. Christie IW, McCabe S. Major complications of epidural analgesia after surgery:
462 results of a six-year survey. *Anaesthesia*. 2007;62(4):335-341. doi:10.1111/j.1365-
463 2044.2007.04992.x
- 464 33. Basques BA, Varthi AG, Golinvaux NS, Bohl DD, Grauer JN. Patient characteristics
465 associated with increased postoperative length of stay and readmission after elective
466 laminectomy for lumbar spinal stenosis. *Spine (Phila Pa 1976)*. Published online 2014.
467 doi:10.1097/BRS.0000000000000276
- 468 34. Lyden J, Binswanger IA. The United States opioid epidemic. *Semin Perinatol*.
469 2019;43(3):123-131. doi:10.1053/j.semperi.2019.01.001

470 **TABLE LEGEND**

471 ***Table 1: Characteristics of included patients between intervention and control group.***

472 Abbreviation: ASA classification= American Society of Anaesthesiologists classification,

473 BMI= Body Mass Index, SD= Standard Deviation

474

475 ***Table 2: Surgical characteristics of included patients between intervention and control***

476 ***group.***

477 P-value <0.05 stands for statistically significant difference which is marked with *.

478 Abbreviation: SD= Standard Deviation

479

480 **FIGURE LEGEND**

481 ***Figure 1: Pain score pre- and postoperative***

482 NRS pain score is presented as means with SD. Abbreviation: OP= operative.

483

484 ***Figure 2: Peri- and postoperative opioid use***

485 Morphine equivalent is presented as means with SD in mg. Abbreviation: OP= operative.


486

487 **ADDITIONAL FILES**

488 Additional File 1 – Opioid conversion table

489 Additional File 2 – Table with NRS pain score difference adjusted for baseline pain.

490



Intervention



Control




Figure 2




Figure 1